Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: J Mol Cell Cardiol. 2010 Jul 23;49(4):587–597. doi: 10.1016/j.yjmcc.2010.07.010

Figure 2.

Figure 2

AMD3100 treatment increases myocardial injury and accentuates LV hypertrophy after infarction. Scar and viable myocardium in the risk region were determined in Masson's trichrome stained LV sections 20 days after surgery. Myocyte cross-sectional area was determined in sections stained with FITC-conjugated wheat germ agglutinin (WGA). (A) Representative Masson's trichrome stained heart short axis sections. (B) Scar as percent of LV was increased in AMD3100- treated hearts after ligation as viable myocardium in the risk region was decreased(n=8-13). (C) Heart weight (HW/BW) was significantly increased in AMD3100-treated mice after ligation (final body weights: Veh Sham, 31.6± 0.8 g; AMD Sham, 30.8± 0.6g: Veh Lig, 30.6±0.8g; AMD Lig, 31.5±0.7g.) (D) Myocyte cross-sectional area in FITC-labeled WGA stained sections was significantly increased in both risk and remote regions in AMD3100-treated hearts after ligation (n=6-8). (E) Representative FITC-labeled WGA stained cross-sections. Values are mean ± SEM. *P<0.05, **P<0.005 vs Vehicle Ligation; † P<0.05 vs Vehicle Sham.